Baxter International Inc. BAX announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy, a severe, debilitating disorder requiring lifelong treatment.
With adoption by the European Commission, Baxter will receive marketing authorization for KIOVIG MMN indication in all European Union Member States- the first centrally-licensed indication for an immunoglobulin preparation for MMN.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in